• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Jim Cramer

Jim Cramer: The Drug Cos. Are at Full Strength

We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
By JIM CRAMER Aug 18, 2021 | 02:33 PM EDT
Stocks quotes in this article: PFE, JNJ, MRK, BMY, GSK, LLY, REGN, ABBV

Sometimes, a run just sneaks up on you and you don't see it until it is too late and you miss the whole darned thing.

That's how I feel about this stealth move in the drug stocks. We keep seeing individual drug stocks running and we want to ascribe the moves to incidences and strengths that are directly related to the companies themselves.

Take Pfizer (PFE) . This stock has been a banshee, an amazing move, especially because of the booster talk and how COVID's delta variant has given it a 2022 tailwind. That will really help as key patents lose exclusivity and make for a multi-year move.

But wait a second. Pfizer may have the boost it needs from the booster. That's not what Johnson & Johnson (JNJ) has. It has the other side of the trade, getting to be the one that many people fear does not provide the protection that Pfizer has, especially against the delta variant -- some say it is much less effective -- even as it has been excellent at keeping people from severe illness.

So what's this stock's excuse for moving up in tandem with a company that's doing better than it in fighting COVID?

Simple: This is a group move, not an individual move. It has to do with the election and how the politicians, after so much posturing about reining drug prices in aren't doing anything at all. This one feels like the multi-year move the drug stocks had in the early '90s after Clinton bashed them in a speech given at Merck's (MRK) New Jersey Headquarters. His inability to follow through invited a rally of immense proportions.

That's what's really driving these stocks: election relief. They could be offering very little that's of import, as is the case with the sleepy Bristol-Myers (BMY) and it doesn't matter, the stock is red hot just touching its 52-week high. Don't get me wrong; I like the consistency and the dividend of Bristol-Myers and think it will win its share of anti-cancer business, plus its Eliquis anti-coagulate is a genuine blockbuster.

But should it be up here? Yes, if you think we are all going to pay a higher multiple now that the Democrats seem to be turning a blind eye to the group.

How about this one? Not that long ago Elliott, the aggressive hedge fund, started calling for big governance changes at GlaxoSmithKline (GSK) . The stock had been a terrible laggard. Now it is on fire.

Or Eli Lilly And Co. (LLY) . You are paying 37-times earnings, because you believe that the Alzheimer's drug rolls back plaque and can potentially reverse that dreaded disease some day. But if you look at the action in that stock, some day is now. It seems to bullish to me, but anything's possible.

Regeneron (REGN) just hit an all-time high, and, why not, it's got a successful treatment for those who get COVID? Again, though not that long ago this company was on the hotseat for charging a great deal for a cholesterol drug. I don't hear any anti-Regeneron talk now.

Finally there is the sneaky AbbVie (ABBV) , which has moved up well with the possibility of Rinvoq -- a key drug to replace lost humira revenues -- getting U.S. approval shortly. Lowest multiple, highest dividend -- it's a big stock for my charitable trust, which you can follow at Action Alerts PLUS member club.

This move isn't over. I could argue given the low valuations, still, it's the third inning and no more.

I like that. Lot of baseball left to play.

(BMY and ABBV are holdings in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells these stocks? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

BMY and ABBV are holdings in Jim Cramer's Action Alerts PLUS member club.

TAGS: Drug Approvals | Pharmaceuticals | Jim Cramer | Health |

More from Jim Cramer

Jim Cramer: I'll Put My Money With 'Boring but Lucrative' Any Day

Jim Cramer
Sep 29, 2021 1:28 PM EDT

Let's look at that recent downgrade of 'dull' Morgan Stanley and see why exciting is best left for the stadiums and amusement parks -- and not stocks.

Jim Cramer: America's Toughest Job? Finding Workers

Jim Cramer
Sep 28, 2021 12:17 PM EDT

It's the question of our time: Where are the people willing to take on these better paying gigs? Let's see what's going on and what we need to happen.

Jim Cramer: Here's How Analysts Can Be Off By a Wide Margin

Jim Cramer
Sep 24, 2021 12:02 PM EDT

Let's look at the reactions to Nike, Costco and Salesforce to see what happens when they're viewed from a real world perspective.

Jim Cramer: It's Pure Insanity That We Don't Make Chips Here in the U.S.

Jim Cramer
Sep 23, 2021 11:05 AM EDT

While the big guns meet at the White House about the global chip shortage, the president and these companies are approaching this all wrong.

Jim Cramer: Go Ahead, Have a Cow, but I Say Powell and Xi Are Bulls

Jim Cramer
Sep 22, 2021 3:51 PM EDT

We rallied, because China's President Xi and Fed Chair Powell made decisions that they knew would lead to rallies.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • 10:44 AM EDT PAUL PRICE

    My Very Best Pick for the Next 12 Months

    American Woodmark . It rarely gets better than th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login